Advertisement
Advertisement
NNVC
NanoViricides Inc.
0.95
USDSponsored
0.00
+0.21%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
0.94
0.00
-0.31%
NNVC Earnings Reports
Positive Surprise Ratio
NNVC beat 13 of 14 last estimates.
93%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.13
Implied change from Q2 26 (Revenue/ EPS)
--
/+18.18%
Implied change from Q3 25 (Revenue/ EPS)
--
/--
NanoViricides Inc. earnings per share and revenue
On Feb 17, 2026, NNVC reported earnings of -0.11 USD per share (EPS) for Q2 26, beating the estimate of -0.14 USD, resulting in a 22.97% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.97% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 18.18% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were NanoViricides Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, NanoViricides Inc. reported EPS of -$0.11, beating estimates by 22.97%, and revenue of $0.00, 0% as expectations.
How did the market react to NanoViricides Inc.'s Q2 2026 earnings?
The stock price moved up 0.97%, changed from $1.03 before the earnings release to $1.04 the day after.
When is NanoViricides Inc. expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for NanoViricides Inc.'s next earnings report?
Based on 4
analysts, NanoViricides Inc. is expected to report EPS of -$0.13 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement